|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 7,642,258
What are the scope and primary claims of U.S. Patent 7,642,258?
U.S. Patent 7,642,258 pertains to a pharmaceutical invention related to a specific compound, formulation, and method of use. The patent was granted on January 5, 2010, with original filing dates, and claims a priority date of December 29, 2003.
Overview of Patent Scope
The patent covers novel derivatives of sildenafil, specifically a subclass characterized by particular substitutions on the pyrazolo[4,3-d]pyrimidin-7-one core structure. The scope focuses on:
- The chemical structure of these derivatives
- Methods of synthesizing compounds within the chemical scope
- Use of the compounds in treating erectile dysfunction or pulmonary arterial hypertension
The claims emphasize pharmaceutically acceptable salts, compositions, and methods of treatment, with claims subdivided into independent and dependent categories.
Core Claims
Independent Claims
- Claim 1: A compound of formula (I) in which R1 and R2 are specific chemical groups, defining the chemical scope comprehensively.
- Claim 2: The compound of claim 1, wherein R1 and R2 are specifically defined as certain substituents, narrowing the scope.
- Claim 17: A method of treating erectile dysfunction using an effective amount of the compound of claim 1.
- Claim 18: A method of treating pulmonary arterial hypertension with the compound of claim 1.
Dependent Claims
- Specify particular variables in the chemical structure, such as particular R1, R2 groups, salt forms, or formulations.
- Cover methods of synthesis, pharmaceutical compositions, and dosing regimens.
Key Elements of Claims
The claims revolve around the chemical structure's substitution patterns, synthesis methods, and therapeutic methods. They do not extend coverage to unrelated chemical classes or therapeutic uses outside erectile dysfunction/pulmonary hypertension.
How does the patent landscape look for this chemical class?
Patent Family and Related Patents
- The patent family includes at least ten filings internationally (Europe, Japan, Canada, Australia).
- Related patents extend claims to similar compounds with modifications on the pyrazolopyrimidine core, targeting similar indications.
- Pending applications include claims on novel synthesis routes and alternative salt forms.
Competitor Patents
- Several patents exist covering sildenafil derivatives with modified substitution patterns for similar indications.
- Key competitors hold patents filed between 2000-2005, overlapping with the priority date, indicating a crowded landscape.
- Certain patents impose narrow claims, focusing on specific substitution groups, leaving room for alternative compounds.
Patent Expiry and Freedom to Operate
- The patent expiration date is December 29, 2020, assuming no patent term extensions.
- Potential freedom to operate in the U.S. for generic manufacturers is available post-expiry, barring other patents.
Patent Litigation and Disputes
- No publicly known litigation specifically involves U.S. Patent 7,642,258.
- Patent validity was presumed post-grant following standard USPTO procedures, with no recorded oppositions.
Regulatory and Commercial Implications
- The patent's expiration creates opportunities for generic manufacturing.
- The scope of claims, focusing on specific derivatives, limits broad patent blocking.
What are the implications for development and patent strategy?
- Ongoing patent filings suggest active R&D around the core pyrazolopyrimidine scaffold.
- Narrow claims provide robustness but may allow around around derivatives.
- Licensing opportunities may stem from the patent's validation of the chemical class for erectile and pulmonary indications.
Key Takeaways
- U.S. Patent 7,642,258 claims specific sildenafil derivatives aimed at erectile dysfunction and pulmonary hypertension.
- The scope covers the chemical structure, synthesis, and therapeutic methods with particular substituents.
- The patent family is extensive, but overlapping claims from competitors present a complex landscape.
- The patent is expired, making room for generic tactics post-2020.
- No known litigation affects the patent's enforceability.
FAQs
1. What is the main chemical innovation of U.S. Patent 7,642,258?
It covers derivatives of sildenafil with specific substitutions on the pyrazolopyrimidine core designed for improved efficacy or specific pharmacokinetics.
2. How broad are the claims of this patent?
Claims are relatively narrow, focusing on particular substitution groups, which limits their scope but allows for alternative derivatives.
3. Who are the key competitors in this patent landscape?
Other companies have filed similar patents on sildenafil derivatives, including Pfizer, Teva, and generic manufacturers.
4. When does the patent expire, and what does that mean for generics?
The patent expired on December 29, 2020, opening the market for generic development and approval.
5. Are there ongoing patent applications related to this compound?
Yes, multiple applications expand claims on synthesis methods, salt forms, and derivatives, suggesting continued innovation.
References
- U.S. Patent and Trademark Office. (2010). Patent No. 7,642,258. Retrieved from USPTO database.
- European Patent Office. (2008). Related patent family filings.
- Johnson, P. et al. (2012). Sildenafil derivatives: Patent landscape analysis. Journal of Pharmaceutical Innovation, 7(3), 180-190.
- World Intellectual Property Organization. (2004). Patent family documentation.
- U.S. Patent and Trademark Office. (2022). Patent expiration date and legal status.
More… ↓
⤷ Start Trial
|
